Clinical trial
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study…
NCT01856218 · Ultragenyx Pharmaceutical Inc, Industry · Completed
Key facts
| NCT number | NCT01856218 |
|---|---|
| Title | An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) |
| Official title | An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7) |
| Lead sponsor | Ultragenyx Pharmaceutical Inc, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Mucopolysaccharidosis Type 7 |
| Intervention type | Drug |
| Interventions | UX003 |
| Enrollment | 3 |
| Start date | Nov 1, 2013 |
| Primary completion | Jul 1, 2016 |
| Completion | Jul 1, 2016 |
| First posted | May 17, 2013 |
| Last update posted | Jan 4, 2019 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: